Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jun 3;9:2855–2865. doi: 10.2147/DDDT.S76358

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 Xu et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License

The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.

PMC Copyright notice

NSCLC patients (n=634) pooled from eight studies to assess whether or not aberrant RUNX3 hypermethylation in NSCLC is associated with a more advanced stage of disease.

Notes: (A) Aberrant RUNX3 hypermethylation was not significantly higher in advanced NSCLC (III and IV) than in early stage NSCLC (I and II; OR 1.21, CI 0.61–2.42, P=0.59). (B) Aberrant RUNX3 hypermethylation was also not significantly higher in poorly differentiated NSCLC than that in moderately and highly differentiated NSCLC (OR 0.65, CI 0.14–2.99, P=0.58). (C) Three included studies investigated relationships between overall survival and RUNX3 hypermethylation. The pooled HR for overall survival showed that RUNX3 hypermethylation was associated with worse survival in NSCLC (HR 3.12, 95% CI 1.47–6.62, P=0.003).

Abbreviations: CI, confidence interval; HR, hazard ratio; OR, odds ratio; M–H, Mantel–Haenszel; NSCLC, non-small cell lung cancer; SE, standard error.